Robert G. Brankamp

Важность для гирудотерапии

Robert Brankamp's contribution to hirudotherapy is the recognition that the leech provides drug-discovery starting points not only for direct thrombin inhibition (the hirudin family) but for inhibition of the upstream Factor Xa node of the coagulation cascade. The conceptual significance of this is substantial: thrombin acts at the very end of coagulation, converting fibrinogen to fibrin, and inhibiting thrombin (whether by hirudin or by argatroban or dabigatran) is a 'late' intervention. Factor Xa, by contrast, sits at the junction of the intrinsic and extrinsic coagulation cascades and amplifies the entire downstream signal — meaning that Factor Xa inhibition can achieve therapeutic anticoagulation at lower compound exposure with potentially better safety margins. The 1990 J Biol Chem paper characterized ghilanten from the South American giant Amazon leech Haementeria ghilianii, building on Tuszynski's 1987 J Biol Chem isolation of antistasin from the Mexican leech Haementeria officinalis. Brankamp showed that the two compounds shared a conserved structural fold (the antistasin family) but with distinct kinetic constants and substrate selectivity profiles. The structural biology that emerged from this work — the antistasin-family canonical fold, the disulfide-stabilized inhibitor scaffold, the reactive-site loop architecture — became the conceptual template that Bayer and Bristol-Myers Squibb later used to design the small-molecule direct oral Factor Xa inhibitors (rivaroxaban, FDA-approved 2011; apixaban, FDA-approved 2012; edoxaban, FDA-approved 2015). The market impact has been enormous. Rivaroxaban and apixaban combined generate over $20 billion in annual global revenue (2024 estimates) and have largely replaced warfarin as the standard anticoagulant for non-valvular atrial fibrillation in the developed world. While neither molecule is a direct leech derivative, both descend conceptually from the antistasin/ghilanten structural template — meaning that Brankamp's late-1980s leech biochemistry has indirectly affected hundreds of millions of patient-years of anticoagulant therapy. ASH considers him the patron of Factor Xa-directed hirudotherapy pharmacology.